The majority of plasma-derived products used in Australia are manufactured from Australian-sourced plasma. Some products are imported, including some coagulation factors and immunoglobulins, either to supplement domestic supplies (for example, intravenous immunoglobulin) or to provide products which are not presently manufactured in Australia, such as fibrinogen concentrates. A review of Australia's plasma fractionation arrangements found that maintenance of product safety, quality and availability would be best achieved by fractionation of Australian plasma continuing locally.1 Other advantages of local production were also noted, in terms of overall costs, turnaround times, management of risks to safety and availability of plasma supplies and, importantly, maintaining the confidence and support of Australian blood donors.
Plasma-derived products are typically prepared from pooled plasma, with a pool often consisting of thousands of donations. All plasma samples are uniquely identified to ensure ongoing traceability. Pooling minimises the infective risk, should the plasma pool be contaminated by a potentially infected donation. Infectious material present in one donation may be rendered below the infectious threshold by dilution in a pool of thousands of donations or may be neutralised by protective antibody present from other donations in the pool.
However, pooled plasma products are usually distributed to many patients, so infectious material not eliminated during manufacturing could potentially cause harm to many recipients. Further serological and nucleic acid testing is also performed on starting pool samples and only pools with acceptable testing results proceed to further manufacturing.
Plasma fractionation
The fractionation process includes physical separation using precipitation and chromatography. Chromatography separates molecules from a liquid solution based on chemical and physical properties, enabling partition and purification of immunoglobulins, clotting factors and albumin from plasma.
The fractionation process also contributes to non-specific reduction of viruses and other pathogens, including prions (although variant Creutzfeldt-Jakob disease has not been identified in Australia). Each component manufactured from Australian plasma undergoes two dedicated pathogen reduction steps. These have been validated to remove or inactivate potential pathogens4 and include:
- dry heat treatment (80oC for 72 hours) or pasteurisation
- use of solvents and detergents
- exposure to low pH conditions
- nanofiltration.
These are performed according to approved manufacturing processes for each product. No confirmed transmissions of viruses have occurred from products used in Australia since effective dedicated pathogen inactivation and removal steps were introduced. However, non-enveloped viruses such as parvovirus B19 and hepatitis A remain a concern for some products, as current viral inactivation or removal techniques are variably effective against these.
Quality control
The fractionation process proceeds under strict regulatory oversight in a highly controlled manufacturing environment. Cleaning and sanitation protocols prevent cross-contamination of batches. Quality control and release testing monitors interim and final products against approved plasma specifications agreed upon by the manufacturer and the TGA.
All therapeutic products used in Australia, whether manufactured locally or imported, are registered on the Australian Register of Therapeutic Goods and must meet the stringent regulatory requirements of the TGA. However, some variations between local and imported products can occur, and these may have clinical consequences. For example, the differences in intravenous immunoglobulin products, such as antibody profile, may reflect the:
- geographic locations, infectious exposures and immunityof the donor population
- plasma collection (whole blood donation, or by apheresis)
- testing performed
- manufacturing methods.